<p>瑞士银行（Bank Julius Baer  Co. Ltd Zurich）在最近向美国证券交易委员会提交的 13F 表格中表示，在第四季度将其在瑞思迈公司（ResMed Inc.，NYSE:RMD - 免费报告）的持股减少了 17.9%。该基金在季度内出售了 5,422 股后，持有瑞思迈的股票共 24,847 股。截至其最近的 SEC 文件，瑞思迈的持股价值为 6,031,000 美元。</p>
<ul>
<li>HCA Healthcare 上涨：减肥药真的构成重大威胁吗？</li>
</ul>
<p>其他一些机构投资者和对冲基金最近也调整了对 RMD 的持股。国际资产投资管理公司（International Assets Investment Management LLC）在第四季度购买了瑞思迈的新股份，价值约 25,000 美元。ORG Partners LLC 在第四季度将其在瑞思迈的持股增加了 181.6%。ORG Partners LLC 现在拥有 107 股瑞思迈的股票，价值 26,000 美元，此前在此期间又购买了 69 股。Imprint Wealth LLC 在第三季度购买了瑞思迈的新股份，价值约 26,000 美元。圣地亚哥的 WFA LLC 在第二季度购买了瑞思迈的新股份，价值约 26,000 美元。最后，Sunbelt Securities Inc.在第三季度购买了瑞思迈的新股份，价值 31,000 美元。54.98% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>瑞思迈股票上涨 0.1%</h2>
<p>周五，NYSE:RMD 的开盘价为 202.55 美元。瑞思迈公司的一年最低价为 198.61 美元，一年最高价为 293.81 美元。该公司的 50 日移动平均价格为 225.07 美元，200 日移动平均价格为 242.81 美元。公司的市值为 295.1 亿美元，市盈率为 19.53，市盈增长比率为 1.29，贝塔值为 0.84。公司的债务与股本比率为 0.06，流动比率为 3.01，速动比率为 2.33。</p>
<p>瑞思迈（NYSE:RMD - 获取免费报告）最近于 4 月 30 日发布了季度财报。该医疗设备提供商报告季度每股收益（EPS）为 2.86 美元，超出分析师一致预期的 2.79 美元，超出幅度为 0.07 美元。瑞思迈的股本回报率为 25.35%，净利润率为 27.44%。该公司季度收入为 14.3 亿美元，而分析师预期为 14.2 亿美元。在去年同期，该公司每股收益为 2.37 美元。与去年同期相比，该季度的收入增长了 10.8%。平均而言，股票分析师预测瑞思迈在当前财政年度的每股收益将达到 11.13 美元。</p>
<h2>瑞思迈分红公告</h2>
<p>该公司最近宣布了季度分红，将于 6 月 18 日支付。5 月 14 日的股东将获得每股 0.60 美元的分红。除息日为 5 月 14 日。这相当于每年 2.40 美元的分红，分红收益率为 1.2%。瑞思迈的分红支付比率目前为 23.14%。</p>
<h2>分析师评级变动</h2>
<p>一些研究分析师最近对 RMD 股票发表了评论。KeyCorp 在 4 月 27 日的研究报告中将瑞思迈的目标价从 302.00 美元下调至 290.00 美元，并对该股票给予 “增持” 评级。富国银行（Wells Fargo  Company）在 5 月 1 日的研究报告中将瑞思迈的目标价从 270.00 美元下调至 227.00 美元，并对该股票给予 “持平” 评级。摩根大通（JPMorgan Chase  Co.）在 4 月 15 日的研究报告中开始覆盖瑞思迈的股票，并给予该公司 “增持” 评级。Piper Sandler 在 1 月 30 日的研究报告中将瑞思迈的目标价从 270.00 美元上调至 275.00 美元，并给予该公司 “中性” 评级。最后，花旗集团（Citigroup）在 4 月 9 日的研究报告中将瑞思迈的目标价从 345.00 美元下调至 340.00 美元，并对该公司给予 “买入” 评级。一位分析师对该股票给予 “强烈买入” 评级，九位给予 “买入” 评级，五位给予 “持有” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 286.18 美元。</p>
<p><strong>阅读我们关于 RMD 的最新研究报告</strong></p>
<h2>内部买卖</h2>
<p>在其他瑞思迈的新闻中，董事彼得·C·法雷尔（Peter C. Farrell）在 4 月 1 日的交易中出售了 2,000 股瑞思迈股票。该股票以平均 225.00 美元的价格出售，总价值为 450,000.00 美元。该交易在向证券交易委员会提交的文件中披露，文件可在此链接查看。此外，首席执行官迈克尔·J·法雷尔（Michael J. Farrell）在 3 月 9 日的交易中出售了 4,991 股公司的股票。该股票以平均 251.03 美元的价格出售，总价值为 1,252,890.73 美元。交易完成后，首席执行官持有公司 466,223 股股票，价值 117,035,959.69 美元。这代表其持股减少了 1.06%。该销售的 SEC 文件提供了更多信息。在过去 90 天内，内部人士出售了价值 4,386,031 美元的 18,973 股公司股票。0.65% 的股票由公司内部人士持有。</p>
<h2>瑞思迈公司简介</h2>
<p>（免费报告）</p>
<p>瑞思迈（ResMed）NYSE: RMD 是一家全球医疗设备和云连接公司，专注于改善患有睡眠呼吸障碍和慢性呼吸疾病的人的治疗效果。公司成立于 1989 年，总部位于加利福尼亚州圣地亚哥，开发、制造和分销一系列设备和软件，供全球患者、临床医生和提供者使用。</p>
<p>瑞思迈的产品组合集中在非侵入性通气和睡眠治疗设备上，包括持续气道正压（CPAP）和双水平设备、面罩及相关配件，用于治疗阻塞性睡眠呼吸暂停和其他呼吸疾病。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，胜过瑞思迈</li>
<li>YETI 在财报超预期和上调前景后反弹</li>
<li>三家领先的量子公司在第一季度财报后的对比</li>
<li>思科的垂直反弹可能仍处于早期阶段</li>
<li>亚马逊与阿里巴巴：现在显然更具价值的选择是其中之一</li>
</ul>
<p><strong>想知道其他对瑞思迈持有股份的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取瑞思迈公司（NYSE:RMD - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJNRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJNRA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资瑞思迈 1,000 美元吗？</h2>
<p>在考虑瑞思迈之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而瑞思迈并不在名单上。</p>
<p>虽然瑞思迈目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

瑞思迈

美国医药设备 ETF - iShares

标普健康医疗设备 ETF - SPDR

<p>瑞士银行瑞士宝银行（Bank Julius Baer & Co. Ltd Zurich）在第四季度将其在瑞思迈（ResMed Inc.）的持股减少了 17.9%，目前持有 24,847 股，市值为 6,031,000 美元。其他机构投资者也调整了他们的持仓。瑞思迈的股票开盘价为 202.55 美元，市值为 295.1 亿美元。该公司报告的季度每股收益（EPS）为 2.86 美元，超出预期，并宣布每股派息 0.60 美元。分析师对该股票的评级意见不一，普遍评级为 “适度买入”，平均目标价为 286.18 美元</p>

<p>Bank Julius Baer &amp; Co. Ltd Zurich cut its position in shares of ResMed Inc. (NYSE:RMD - Free Report) by 17.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 24,847 shares of the medical equipment provider's stock after selling 5,422 shares during the quarter. Bank Julius Baer &amp; Co. Ltd Zurich's holdings in ResMed were worth $6,031,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>瑞士银行（Bank Julius Baer  Co. Ltd Zurich）在最近向美国证券交易委员会提交的 13F 表格中表示，在第四季度将其在瑞思迈公司（ResMed Inc.，NYSE:RMD - 免费报告）的持股减少了 17.9%。该基金在季度内出售了 5,422 股后，持有瑞思迈的股票共 24,847 股。截至其最近的 SEC 文件，瑞思迈的持股价值为 6,031,000 美元。</p>
</div><ul>
<li>HCA Healthcare Rallies: Weight-loss drugs really a big threat?</li>
</ul>
<div class="lb-trans"><ul>
<li>HCA Healthcare 上涨：减肥药真的构成重大威胁吗？</li>
</ul>
</div><p>A number of other institutional investors and hedge funds also recently modified their holdings of RMD. International Assets Investment Management LLC purchased a new position in shares of ResMed in the fourth quarter worth about $25,000. ORG Partners LLC increased its holdings in shares of ResMed by 181.6% in the fourth quarter. ORG Partners LLC now owns 107 shares of the medical equipment provider's stock worth $26,000 after purchasing an additional 69 shares during the period. Imprint Wealth LLC bought a new stake in shares of ResMed during the 3rd quarter valued at about $26,000. WFA of San Diego LLC purchased a new position in ResMed in the 2nd quarter worth approximately $26,000. Finally, Sunbelt Securities Inc. purchased a new stake in shares of ResMed during the 3rd quarter valued at $31,000. 54.98% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他一些机构投资者和对冲基金最近也调整了对 RMD 的持股。国际资产投资管理公司（International Assets Investment Management LLC）在第四季度购买了瑞思迈的新股份，价值约 25,000 美元。ORG Partners LLC 在第四季度将其在瑞思迈的持股增加了 181.6%。ORG Partners LLC 现在拥有 107 股瑞思迈的股票，价值 26,000 美元，此前在此期间又购买了 69 股。Imprint Wealth LLC 在第三季度购买了瑞思迈的新股份，价值约 26,000 美元。圣地亚哥的 WFA LLC 在第二季度购买了瑞思迈的新股份，价值约 26,000 美元。最后，Sunbelt Securities Inc.在第三季度购买了瑞思迈的新股份，价值 31,000 美元。54.98% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>ResMed Stock Up 0.1%</h2>
<div class="lb-trans"><h2>瑞思迈股票上涨 0.1%</h2>
</div><p>NYSE:RMD opened at $202.55 on Friday. ResMed Inc. has a 1-year low of $198.61 and a 1-year high of $293.81. The firm's 50-day moving average price is $225.07 and its 200-day moving average price is $242.81. The company has a market capitalization of $29.51 billion, a PE ratio of 19.53, a P/E/G ratio of 1.29 and a beta of 0.84. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.01 and a quick ratio of 2.33.</p>
<div class="lb-trans"><p>周五，NYSE:RMD 的开盘价为 202.55 美元。瑞思迈公司的一年最低价为 198.61 美元，一年最高价为 293.81 美元。该公司的 50 日移动平均价格为 225.07 美元，200 日移动平均价格为 242.81 美元。公司的市值为 295.1 亿美元，市盈率为 19.53，市盈增长比率为 1.29，贝塔值为 0.84。公司的债务与股本比率为 0.06，流动比率为 3.01，速动比率为 2.33。</p>
</div><p>ResMed (NYSE:RMD - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The medical equipment provider reported $2.86 EPS for the quarter, topping analysts' consensus estimates of $2.79 by $0.07. ResMed had a return on equity of 25.35% and a net margin of 27.44%.The firm had revenue of $1.43 billion for the quarter, compared to analysts' expectations of $1.42 billion. During the same period in the previous year, the firm posted $2.37 EPS. The business's revenue for the quarter was up 10.8% compared to the same quarter last year. On average, equities analysts predict that ResMed Inc. will post 11.13 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>瑞思迈（NYSE:RMD - 获取免费报告）最近于 4 月 30 日发布了季度财报。该医疗设备提供商报告季度每股收益（EPS）为 2.86 美元，超出分析师一致预期的 2.79 美元，超出幅度为 0.07 美元。瑞思迈的股本回报率为 25.35%，净利润率为 27.44%。该公司季度收入为 14.3 亿美元，而分析师预期为 14.2 亿美元。在去年同期，该公司每股收益为 2.37 美元。与去年同期相比，该季度的收入增长了 10.8%。平均而言，股票分析师预测瑞思迈在当前财政年度的每股收益将达到 11.13 美元。</p>
</div><h2>ResMed Dividend Announcement</h2>
<div class="lb-trans"><h2>瑞思迈分红公告</h2>
</div><p>The company also recently declared a quarterly dividend, which will be paid on Thursday, June 18th. Stockholders of record on Thursday, May 14th will be issued a dividend of $0.60 per share. The ex-dividend date is Thursday, May 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 1.2%. ResMed's dividend payout ratio is presently 23.14%.</p>
<div class="lb-trans"><p>该公司最近宣布了季度分红，将于 6 月 18 日支付。5 月 14 日的股东将获得每股 0.60 美元的分红。除息日为 5 月 14 日。这相当于每年 2.40 美元的分红，分红收益率为 1.2%。瑞思迈的分红支付比率目前为 23.14%。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of research analysts recently commented on RMD shares. KeyCorp reduced their target price on ResMed from $302.00 to $290.00 and set an &#34;overweight&#34; rating on the stock in a research note on Monday, April 27th. Wells Fargo &amp; Company decreased their price target on shares of ResMed from $270.00 to $227.00 and set an &#34;equal weight&#34; rating on the stock in a research note on Friday, May 1st. JPMorgan Chase &amp; Co. assumed coverage on shares of ResMed in a research note on Wednesday, April 15th. They issued an &#34;overweight&#34; rating for the company. Piper Sandler raised their price objective on ResMed from $270.00 to $275.00 and gave the company a &#34;neutral&#34; rating in a research note on Friday, January 30th. Finally, Citigroup lowered their target price on ResMed from $345.00 to $340.00 and set a &#34;buy&#34; rating for the company in a research note on Thursday, April 9th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $286.18.</p>
<div class="lb-trans"><p>一些研究分析师最近对 RMD 股票发表了评论。KeyCorp 在 4 月 27 日的研究报告中将瑞思迈的目标价从 302.00 美元下调至 290.00 美元，并对该股票给予 “增持” 评级。富国银行（Wells Fargo  Company）在 5 月 1 日的研究报告中将瑞思迈的目标价从 270.00 美元下调至 227.00 美元，并对该股票给予 “持平” 评级。摩根大通（JPMorgan Chase  Co.）在 4 月 15 日的研究报告中开始覆盖瑞思迈的股票，并给予该公司 “增持” 评级。Piper Sandler 在 1 月 30 日的研究报告中将瑞思迈的目标价从 270.00 美元上调至 275.00 美元，并给予该公司 “中性” 评级。最后，花旗集团（Citigroup）在 4 月 9 日的研究报告中将瑞思迈的目标价从 345.00 美元下调至 340.00 美元，并对该公司给予 “买入” 评级。一位分析师对该股票给予 “强烈买入” 评级，九位给予 “买入” 评级，五位给予 “持有” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 286.18 美元。</p>
</div><p><strong>Read Our Latest Research Report on RMD</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 RMD 的最新研究报告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In other ResMed news, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $225.00, for a total value of $450,000.00. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this hyperlink. Also, CEO Michael J. Farrell sold 4,991 shares of the business's stock in a transaction on Monday, March 9th. The stock was sold at an average price of $251.03, for a total value of $1,252,890.73. Following the completion of the transaction, the chief executive officer owned 466,223 shares of the company's stock, valued at $117,035,959.69. This represents a 1.06% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 18,973 shares of company stock valued at $4,386,031. 0.65% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他瑞思迈的新闻中，董事彼得·C·法雷尔（Peter C. Farrell）在 4 月 1 日的交易中出售了 2,000 股瑞思迈股票。该股票以平均 225.00 美元的价格出售，总价值为 450,000.00 美元。该交易在向证券交易委员会提交的文件中披露，文件可在此链接查看。此外，首席执行官迈克尔·J·法雷尔（Michael J. Farrell）在 3 月 9 日的交易中出售了 4,991 股公司的股票。该股票以平均 251.03 美元的价格出售，总价值为 1,252,890.73 美元。交易完成后，首席执行官持有公司 466,223 股股票，价值 117,035,959.69 美元。这代表其持股减少了 1.06%。该销售的 SEC 文件提供了更多信息。在过去 90 天内，内部人士出售了价值 4,386,031 美元的 18,973 股公司股票。0.65% 的股票由公司内部人士持有。</p>
</div><h2>ResMed Profile</h2>
<div class="lb-trans"><h2>瑞思迈公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>ResMed NYSE: RMD is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.</p>
<div class="lb-trans"><p>瑞思迈（ResMed）NYSE: RMD 是一家全球医疗设备和云连接公司，专注于改善患有睡眠呼吸障碍和慢性呼吸疾病的人的治疗效果。公司成立于 1989 年，总部位于加利福尼亚州圣地亚哥，开发、制造和分销一系列设备和软件，供全球患者、临床医生和提供者使用。</p>
</div><p>ResMed's product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.</p>
<div class="lb-trans"><p>瑞思迈的产品组合集中在非侵入性通气和睡眠治疗设备上，包括持续气道正压（CPAP）和双水平设备、面罩及相关配件，用于治疗阻塞性睡眠呼吸暂停和其他呼吸疾病。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than ResMed</li>
<li>YETI Rallies After Earnings Beat and Raised Outlook</li>
<li>How the 3 Leading Quantum Firms Stack Up After Q1 Earnings</li>
<li>Cisco’s Vertical Rally May Still Be in the Early Innings</li>
<li>Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过瑞思迈</li>
<li>YETI 在财报超预期和上调前景后反弹</li>
<li>三家领先的量子公司在第一季度财报后的对比</li>
<li>思科的垂直反弹可能仍处于早期阶段</li>
<li>亚马逊与阿里巴巴：现在显然更具价值的选择是其中之一</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding RMD?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对瑞思迈持有股份的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取瑞思迈公司（NYSE:RMD - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJNRA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=RMD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in ResMed Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资瑞思迈 1,000 美元吗？</h2>
</div><p>Before you consider ResMed, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑瑞思迈之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ResMed wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而瑞思迈并不在名单上。</p>
</div><p>While ResMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然瑞思迈目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Bank Julius Baer & Co. Ltd Zurich Lowers Stock Position in ResMed Inc. $RMD

Market Beat

HCA控股

科凯国际

富国银行

摩根大通

Piper Sandler Cos

花旗

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

CITIGROUP INC 6.250 NON CUM SER II PFD WI

苏黎世的瑞士宝盛银行有限公司减少了其在瑞思迈公司 $RMD 的股票持仓